Literature DB >> 2544307

Inhibition of topoisomerases by fredericamycin A.

M D Latham1, C K King, P Gorycki, T L Macdonald, W E Ross.   

Abstract

Fredericamycin is an antibiotic product of Streptomyces griseus that exhibits modest antitumor activity in vivo and in vitro. Because of its unique structure and the absence of a clearly defined mechanism of action, we examined the effects of this compound on L1210 cells in culture as well as on several enzymes that bind to DNA. Fredericamycin exhibits an IC50 of 4.4 microM toward L1210 cells, and its cytotoxicity is a function of the time of exposure as well as drug dose. No DNA breakage was observed in L1210 cells or isolated nuclei following exposure to highly lethal concentrations of fredericamycin. As a first step toward understanding its mechanism of action, we examined the effect of fredericamycin on several enzymes involved in DNA metabolism. The catalytic activity of both DNA topoisomerases I and II were totally inhibited by fredericamycin concentrations of 4.4 and 7.4 microM, respectively. Fredericamycin blocked etoposide-stimulated DNA cleavage by topoisomerase II both in vitro and in isolated nuclei. In addition, the drug inhibits DNA polymerase a in vitro, exhibiting an IC50 of 93 microM. These diverse actions of fredericamycin do not enable us to draw conclusions regarding its mechanism of antitumor effect but clearly identify it as a compound of pharmacologic interest.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544307     DOI: 10.1007/BF00300237

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme.

Authors:  F H Drake; J P Zimmerman; F L McCabe; H F Bartus; S R Per; D M Sullivan; W E Ross; M R Mattern; R K Johnson; S T Crooke
Journal:  J Biol Chem       Date:  1987-12-05       Impact factor: 5.157

2.  DNA topoisomerases as targets for cancer therapy.

Authors:  W E Ross
Journal:  Biochem Pharmacol       Date:  1985-12-15       Impact factor: 5.858

3.  Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases.

Authors:  L F Liu; J L Davis; R Calendar
Journal:  Nucleic Acids Res       Date:  1981-08-25       Impact factor: 16.971

4.  Cleavage of DNA by mammalian DNA topoisomerase II.

Authors:  L F Liu; T C Rowe; L Yang; K M Tewey; G L Chen
Journal:  J Biol Chem       Date:  1983-12-25       Impact factor: 5.157

5.  Reconstitution of intercalator-induced DNA scission by an active component from nuclear extracts.

Authors:  J Filipski; J Yin; K W Kohn
Journal:  Biochim Biophys Acta       Date:  1983-10-13

6.  DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

Authors:  A J Wozniak; W E Ross
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

7.  Structure of fredericamycin A, an antitumor antibiotic of a novel skeletal type; spectroscopic and mass spectral characterization.

Authors:  R Misra; R C Pandey; B D Hilton; P P Roller; J V Silverton
Journal:  J Antibiot (Tokyo)       Date:  1987-06       Impact factor: 2.649

8.  Magnetic resonance studies of fredericamycin A: evidence for O2-dependent free-radical formation.

Authors:  B D Hilton; R Misra; J L Zweier
Journal:  Biochemistry       Date:  1986-09-23       Impact factor: 3.162

9.  Fredericamycin A, a new antitumor antibiotic. II. Biological properties.

Authors:  D J Warnick-Pickle; K M Byrne; R C Pandey; R J White
Journal:  J Antibiot (Tokyo)       Date:  1981-11       Impact factor: 2.649

10.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

Authors:  Y H Hsiang; R Hertzberg; S Hecht; L F Liu
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

  10 in total
  5 in total

1.  Synthesis and Biological Evaluation of Kibdelone C and Its Simplified Derivatives.

Authors:  Janjira Rujirawanich; Soyeon Kim; Ai-Jun Ma; John R Butler; Yizhong Wang; Chao Wang; Michael Rosen; Bruce Posner; Deepak Nijhawan; Joseph M Ready
Journal:  J Am Chem Soc       Date:  2016-08-09       Impact factor: 15.419

2.  Identification and utility of FdmR1 as a Streptomyces antibiotic regulatory protein activator for fredericamycin production in Streptomyces griseus ATCC 49344 and heterologous hosts.

Authors:  Yihua Chen; Evelyn Wendt-Pienkowski; Ben Shen
Journal:  J Bacteriol       Date:  2008-06-13       Impact factor: 3.490

3.  Activation and enhancement of Fredericamycin A production in deepsea-derived Streptomyces somaliensis SCSIO ZH66 by using ribosome engineering and response surface methodology.

Authors:  Yonghe Zhang; Huiming Huang; Shanshan Xu; Bo Wang; Jianhua Ju; Huarong Tan; Wenli Li
Journal:  Microb Cell Fact       Date:  2015-05-01       Impact factor: 5.328

4.  High-throughput screen of natural product libraries for hsp90 inhibitors.

Authors:  Jason Davenport; Maurie Balch; Lakshmi Galam; Antwan Girgis; Jessica Hall; Brian S J Blagg; Robert L Matts
Journal:  Biology (Basel)       Date:  2014-02-10

5.  Synthetic Approach to the ABCD Ring System of Anticancer Agent Fredericamycin A via Claisen Rearrangement and Ring-Closing Metathesis as Key Steps.

Authors:  Sambasivarao Kotha; Subba Rao Cheekatla; Ambareen Fatma
Journal:  ACS Omega       Date:  2019-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.